The higher levels of IL-2 observed in disease-free patients can contribute to make the effect of NATC more stable by promoting the recruitment and activation of natural killer (NK) and cytotoxic CD8+ T lymphocytes at the tumor site, improving the ADCC mediated by trastuzumab [52,53]. This evidence concerns the gene CD8A and neoplasm.